Bavarian Nordic hunting for RSV partners: "If the firm is too small, we might as well consider launching ourselves"

Bavarian Nordic’s recent deal in China has some pundits guessing that more partnerships are on the way. Even so, the company’s CFO Henrik Juuel says if the bidders aren’t the right size, it might be in Bavarian’s best interest to commercialize its RSV vaccine itself.

Photo: Bavarian Nordic / PR

As the ink dries on the deal Bavarian Nordic just signed with a Shanghai-based partner, a question emerges: Having found a partner in China, what will the Danish pharmaceutical firm do with its RSV vaccine candidate in the US and Europe?

According to the company’s CFO, Henrik Juuel, the answer is the same – find partners. The firm is not in a rush, however.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs